Lantheus To Buy Neuraceq Owner Life Molecular Imaging For Upfront Payment Of $350 Mln

Lantheus Holdings

93.12 USD -5.28%

• Charts
• News
• Analysen

Kaufen / Verkaufen

(RTTNews) - Lantheus Holdings Inc. (LNTH), a radiopharmaceutical-focused company, announced Monday a definitive agreement to acquire Life Molecular Imaging Ltd., a unit of Life Healthcare Group Holdings Ltd,. The all-cash deal consists of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments.

The acquisition is expected to immediately enhance Lantheus near and long-term growth profile and establish a commercial Alzheimers disease or AD franchise with the addition of Neuraceq (florbetaben F18 injection).

The transaction is expected to be accretive to Lantheus' adjusted earnings per share within the first 12 months.

The deal is between Lantheus Medical Imaging, Inc., Lantheus Radiopharmaceuticals UK Limited or Lantheus UK, Life Medical Group Limited, and Life Healthcare Group Holdings Limited. Under the deal terms, Lantheus UK will pay an upfront amount of $350 million, payable in cash at closing, and potential additional net sales earnout and milestone payments in an aggregate additional cash amount of up to $400 million.

In addition, Lantheus UK may pay up to $30 million towards Sellers retained future contingent liabilities under certain contractual arrangements.

The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the second half of 2025, subject to customary closing conditions.

Life Molecular is involved in advancing novel Positron Emission Tomography or PET radiopharmaceutical diagnostics.

Lantheus said the acquisition would enhance its growth profile with Neuraceq, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimers Disease.

Neuraceq is a globally approved, F-18 radioactive diagnostic agent indicated for PET imaging of the brain to estimate -amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline. Neuraceq can be used to confirm eligibility for new AD therapies.

Life Molecular also provides robust R&D capabilities, a strong commercial infrastructure, and an established international presence, which Lantheus plans to utilize to accelerate the development, advancement, and commercialization of the combined companys pipeline.

Brian Markison, CEO of Lantheus, said the acquisition aligns with its strategy to drive long-term growth and value creation by investing in high-potential, complementary assets and R&D capabilities to strengthen radiopharmaceutical leadership. The deal is a natural extension of the companies' existing RM2 partnership.

The transaction builds on Lantheus June 2024 acquisition of the global rights to LMIs clinical-stage radiotherapeutic and radiodiagnostic pair, 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2, which target gastrin-releasing peptide receptor (GRPR) for prostate, breast and other cancers.

For More Such Health News, visit rttnews.com